ECSP19024033A - Composiciones de tesofensina - Google Patents

Composiciones de tesofensina

Info

Publication number
ECSP19024033A
ECSP19024033A ECSENADI201924033A ECDI201924033A ECSP19024033A EC SP19024033 A ECSP19024033 A EC SP19024033A EC SENADI201924033 A ECSENADI201924033 A EC SENADI201924033A EC DI201924033 A ECDI201924033 A EC DI201924033A EC SP19024033 A ECSP19024033 A EC SP19024033A
Authority
EC
Ecuador
Prior art keywords
compositions
thesophensin
tesofensin
overweight
obesity
Prior art date
Application number
ECSENADI201924033A
Other languages
English (en)
Inventor
Bruno Racheboeuf
Original Assignee
Saniona As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Saniona As filed Critical Saniona As
Publication of ECSP19024033A publication Critical patent/ECSP19024033A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con composiciones farmacéuticas que comprenden tesofensina como principio activo, sales farmacéuticamente aceptables o derivados de la misma, y su uso en la preparación de medicamentos indicados para la prevención y el tratamiento de sobrepeso, obesidad y diabetes mellitus tipo 2.
ECSENADI201924033A 2016-09-07 2019-04-05 Composiciones de tesofensina ECSP19024033A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16187596 2016-09-07
EP16187813 2016-09-08

Publications (1)

Publication Number Publication Date
ECSP19024033A true ECSP19024033A (es) 2019-04-30

Family

ID=59914436

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201924033A ECSP19024033A (es) 2016-09-07 2019-04-05 Composiciones de tesofensina

Country Status (15)

Country Link
US (1) US9949964B2 (es)
EP (1) EP3509597A1 (es)
JP (1) JP2019526641A (es)
KR (1) KR20190050784A (es)
AU (1) AU2017324406A1 (es)
BR (1) BR112019004033A2 (es)
CA (1) CA3032349A1 (es)
CO (1) CO2019002853A2 (es)
CR (1) CR20190142A (es)
DO (1) DOP2019000052A (es)
EC (1) ECSP19024033A (es)
IL (1) IL264503A (es)
MX (1) MX2019002647A (es)
RU (1) RU2019109050A (es)
WO (1) WO2018046599A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018295387B2 (en) 2017-07-07 2024-02-15 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the prevention or treatment of systemic diseases in cats

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4140756A (en) * 1976-06-10 1979-02-20 Mead Johnson & Company Film-coated matrix core tablet
JPS6038322A (ja) * 1983-08-11 1985-02-27 Fujisawa Pharmaceut Co Ltd ジヒドロピリジンａ物質含有易溶性固形製剤
US6288079B1 (en) * 1996-02-22 2001-09-11 Neurosearch A/S Tropane-derivatives, their preparation and use
US5977158A (en) * 1996-11-28 1999-11-02 Novo Nordisk A/S Pharmaceutical formulations comprising levormeloxifene compounds
US6420473B1 (en) * 2000-02-10 2002-07-16 Bpsi Holdings, Inc. Acrylic enteric coating compositions
US7125563B2 (en) * 2002-04-12 2006-10-24 Dava Pharmaceuticals, Inc. Sustained release pharmaceutical preparations and methods for producing the same
DE102004004965B4 (de) 2004-01-31 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung eines 2-(Ethoxymethyl)-tropanderivates
EP1779851A1 (en) 2005-10-31 2007-05-02 Boehringer Ingelheim Pharma GmbH & Co.KG Treatment of diabetes
CA2709861A1 (en) 2007-12-20 2009-07-02 Neurosearch A/S Pharmaceutical compositions
US20120115837A1 (en) 2009-04-30 2012-05-10 Takeda Pharmaceutical Company Limited Solid Preparation
US10610489B2 (en) * 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
PL2814473T3 (pl) 2012-02-16 2019-06-28 Saniona A/S Kompozycje farmaceutyczne do terapii skojarzonej

Also Published As

Publication number Publication date
DOP2019000052A (es) 2019-05-15
EP3509597A1 (en) 2019-07-17
US20180064700A1 (en) 2018-03-08
BR112019004033A2 (pt) 2019-05-28
WO2018046599A1 (en) 2018-03-15
KR20190050784A (ko) 2019-05-13
MX2019002647A (es) 2019-07-01
RU2019109050A (ru) 2020-10-08
CO2019002853A2 (es) 2019-08-20
US9949964B2 (en) 2018-04-24
JP2019526641A (ja) 2019-09-19
AU2017324406A1 (en) 2019-05-02
CA3032349A1 (en) 2018-03-15
IL264503A (en) 2019-02-28
CR20190142A (es) 2019-05-22

Similar Documents

Publication Publication Date Title
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CL2018002718A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
SV2018005687A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
CL2019003309A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
CL2019002745A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
CR20160518A (es) Compuestos para tratar atrofia muscular espinal
BR112017025108A2 (pt) compostos seletivos de pyy e usos dos mesmos
CL2018002758A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue.
DOP2016000226A (es) Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
CL2020000747A1 (es) Formulaciones de niraparib.
CL2019002744A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
CL2019003294A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
CR20140144A (es) Derivados de estra-1,3,5 (10), 16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
DOP2015000170A (es) Compuestos químicos
AR099569A1 (es) Derivados de insulina y los usos médicos de estos
CL2015000039A1 (es) Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis.
BR112019005318A2 (pt) compostos de aza-indazol para uso em lesões no tendão e/ou ligamento
CR20160529A (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
BR112015010223A2 (pt) compostos tricíclicos para o uso no tratamento e/ou controle de obesidade
ECSP19024033A (es) Composiciones de tesofensina
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
AR109630A1 (es) Composiciones farmacéuticas de tesofensina
BR112017024356A2 (pt) clonidina e/ou derivados de clonidina para uso na prevenção de lesão na pele resultante de radioterapia
AR110598A1 (es) Profármacos de principios activos citotóxicos con grupos enzimáticamente escindibles